login

Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of low-dose heparin

American Journal of Obstetrics and GynecologyPublished 1 March 1983
Daniel L. Clarke‐Pearson, R. Edward Coleman, Ingrid S. Synan, Wanda Hinshaw, William T. Creasman
Citations135
SJR quartileQ1
SJR score2.77
SNIP2.75

TL;DR

Low-dose heparin does not afford any prophylactic benefit to patients undergoing major pelvic operative procedures for gynecologic malignancy and there was no statistical difference in the incidence of proximal deep vein thrombosis, calf vein thROMBosis, or pulmonary emboli between the control and low-dose Heparin groups.

Abstract

One hundred eighty-five patients undergoing operation for gynecologic malignancy participated in a randomized controlled trial of low-dose heparin prophylaxis. Prospective surveillance for deep venous thrombosis was performed with daily fibrinogen 125I counting in the legs and impedance plethysmography. Twelve of 97 (12.4%) patients in the control group and 13 of 88 (14.8%) patients in the low-dose heparin group developed a venous thromboembolic complication. There was no statistical difference in the incidence of proximal deep vein thrombosis, calf vein thrombosis, or pulmonary emboli between the control and low-dose heparin groups. Low-dose heparin does not afford any prophylactic benefit to patients undergoing major pelvic operative procedures for gynecologic malignancy.

Keywords

MedicineHealth Professions